One hundred febrile episodes in 89 neutropenic patients after cytotoxic chemotherapy were randomized to be treated with either ceftazidime or imipenem as initial monotherapy. The clinical characteristics of the two groups of patients were comparable. The response of the fever in patients who received imipenem was significantly better than that in those who received ceftazidime (77 versus 56%, respectively; P = 0.04), especially in those with microbiologically documented infection (81 versus 33%, respectively; P = 0.02). The in vitro susceptibilities and the clinical responses suggested that, with the possible exception of Pseudomonas spp., imipenem was more effective than ceftazidime in treating neutropenic infections caused by both gram-positive and -negative organisms. An additional 23 and 21% of the patients in the ceftazidime and imipenem groups, respectively, responded to the addition of cloxaciUlin and amikacin following failure of monotherapy. The majority of the treatment failures, relapses, and superinfections were related to resistant infective organisms such as methiciBlin-resistant Staphylococcus spp. and Pseudomonas spp. or disseminated fungal infections.
In the management of hematological malignancies, reversible bone marrow depression by cytotoxic chemotherapy inevitablly accompanies the effort to maximize the efficacy of treatment. Prompt administration of empiric broad-spectrum antibiotic therapy to neutropenic patients who become febrile is essential (13, 16) . A combination of intravenous antibiotics consisting of an aminoglycoside and an antipseudomonal penicillin or a cephalosporin is often recommended to provide broad-spectrum coverage, to achieve a synergistic effect, and to reduce the likelihood of emergence of resistant organisms (11, 18) . However, the antibiotic combinations, especially those containing an aminoglycoside, are potentially toxic (9) . Single-agent therapy in the management of neutropenic infections has been encouraged by the availability of new antibiotics with broad spectra of antibacterial activity. As this approach has the potential risk of allowing the emergence of resistant organisms during therapy, its clinical role remains uncertain. New agents, including ceftazidime, imipenem-cilastatin, and ciprofloxacin, have been studied and have been shown to be useful as initial monotherapy for febrile neutropenic patients (1, 2, 5, 9, 10, 14, 17, 19, 21, 22) . We report here the results of our prospective randomized study in which we compared the efficacy and safety of ceftazidime and imipenem as initial monotherapy for our febrile neutropenic patients after cytotoxic chemotherapy. For patients who failed to respond to monotherapy, the effectiveness ofthe subsequent addition of combination antibiotics was assessed.
MATERIALS AND METHODS
Patients with hematological malignancies who were treated in the University Department of Medicine, Queen Mary Hospital, and who became febrile while they were neutropenic were eligible for entry into the study. Febrile * dures (e.g., fiber-optic bronchoscopy) were performed when indicated. The organisms isolated from cultures were identified by routine microbiological methods, and susceptibilities of the organisms to antimicrobial agents were determined by the break-point method on agar dilution or by the disk diffusion technique. Break points greater than 4 and 8 ,ug/ml were used to denote resistance to imipenem and ceftazidime, respectively.
All patients were treated with ceftazidime or imipenem and were assessed at 72 h for their response to therapy. For patients who had good responses, either drug was continued for at least a total of 7 days or for 4 days after the patient became afebrile, whichever was longer, unless an adverse reaction, clinical deterioration, or death occurred. For those who did not respond or who had clinical deterioration, cloxacillin given at 1 g intravenously every 6 h and amikacin given at 5 mg/kg of body weight intravenously every 8 h were given in addition to the original monotherapy (ceftazidime or imipenem). Amikacin levels in serum were determined (preand postinfusion) within 48 h, and the dose of amikacin was adjusted accordingly. The three antibiotics were continued for at least another 72 h for the second assessment of response, unless there was an adverse reaction, clinical deterioration, or death. For those patients who responded to the combination antibiotics, the drugs were continued for at least another 4 days after they had become afebrile or a total of 7 days, whichever was longer. For those who had not responded, further management such as empiric amphotericin B therapy was considered (6) . Vancomycin was used if there were clinically suspected or microbiologically documented gram-positive infections. No patient was given a leukocyte transfusion at any time (17) .
If a primary focus of infection was apparent or a positive culture was obtained during the study, the same antibiotic regimen was continued if the patient was responding to therapy. Otherwise, the antibiotic therapy was altered according to the susceptibility of the organism or the clinical setting.
Fever of unknown origin was diagnosed when no clinical, radiological, or bacteriological evidence of infection was found. Patients were considered to have clinically suspected infection if they had fever and other clinical evidence of an infection, even though the infective organisms were not isolated. Response was defined as complete disappearance of all clinical and laboratory evidence of infection, including fever. Relapse was defined as the reappearance of the same infection within 7 days after discontinuation of the antibiotics. Superinfection was defined as an infection by a different organism or at a different site if no organism could be isolated from the original site and which occurred during treatment with the antibiotics. The chi-square test with the Yates correction was used to compare response rates and proportions.
Informed consent was obtained from all patients. The study protocol was approved by the Ethics Committee of the Faculty of Medicine, University of Hong Kong.
RESULTS
During a 12-month period (August 1988 to July 1989), 92 neutropenic patients entered the study, and there were 103 febrile episodes. Only 100 episodes (in 89 patients) were evaluable. The other three episodes (in three patients) were excluded because they had previously received antibiotics.
There were 44 males (49%) and 45 females (51%). The median age was 38 years (mean age, 36.8 years; range, 16 to imipenem groups. Patients who received imipenem as monotherapy had a significantly better response than did those who received ceftazidime alone (81 versus 33%, respectively; P = 0.02). Similarly, for patients with microbiologically documented infection, those who received imipenem also had a better response (81 versus 33%, respectively; P = 0.02). On the other hand, for patients with fever of unknown origin and clinically suspected infection, the responses of the two groups were similar. An additional 23 and 21% of the febrile cases in the ceftazidime and imipenem groups, respectively, responded to combination antibiotics following the failure of monotherapy. The overall response rate to either monotherapy or combination therapy was also higher in the imipenem group (98 versus 79%, respectively; P = 0.01). When the second infective episode was excluded and only the first episode was counted (n = 89) in each patient, similar response rates were observed (Table 2) . Tables 3 and 4 show the clinical responses to monotherapy according to clinical sites of infection and the organisms that were isolated, respectively. Multiple clinical sites were involved in 11 of the 100 (11%) febrile episodes (6 episodes in the ceftazidime group and 5 episodes in the imipenem group), and more than one infective organism was isolated in 9 (9%) febrile episodes (5 episodes in the ceftazidime group and 4 episodes in the imipenem group). Because of the small number of cases in each subgroup, the differences observed in Tables 3 and 4 were not statistically significant. All together, there were 4 patients with relapses and 14 patients with superinfections, with no significant differences between the ceftazidime and imipenem groups (Table 1) . Of the 14 episodes of superinfection, 9 (64%) were caused by more than one organism. The patterns of relapse and super- infection are shown in Table 5 . They were commonly due to staphylococcal, pseudomonal, or fungal infections. Relapses and superinfections caused by Pseudomonas spp. appeared to be more frequent in the imipenem group (6 of 18 versus 1 of 11 in the ceftazidime group), but the difference was not statistically significant. The antibiotic susceptibilities of all the organisms isolated from 44 patients are shown in Table 6 . A higher proportion of gram-positive organisms was resistant to ceftazidime (68%), while a smaller proportion (20%) was resistant to imipenem. There appeared to be a higher incidence of resistance of some gram-negative organisms to ceftazidime as well, except that Pseudomonas spp. appeared to have a higher incidence of resistance to imipenem. However, all the differences observed were not statistically significant because of the small number of cases in each subgroup. Twenty-five percent of the Staphylococcus aureus isolates were resistant to cloxacillin, and 5% of the Pseudomonas spp. were resistant to amikacin.
Of the 11 febrile episodes that did not respond to ceftazidime or its combination with the addition of cloxacillin and amikacin, 9 febrile episodes responded to another, alternative therapy ( Table 2 ). There of the febrile episodes responded to vancomycin, one responded to empirical amphotericin B, one responded to high-dose co-trimoxazole, one responded to piperacillin, and three responded to imipenem. The remaining two patients died from progression of their underlying blood diseases. The only patient in the imipenem group who did not respond to either imipenem or its combination was subsequently found to have disseminated candidiasis which responded to amphotericin B therapy (Table 2) .
Both ceftazidime and imipenem were well tolerated by patients. Three patients developed skin rashes that required the cessation of antibiotic therapy (two after ceftazidime and one after imipenem therapy). Three patients had significant nausea and vomiting that required antiemetic therapy after imipenem but none after ceftazidime administration. No patients developed central nervous system toxicity.
DISCUSSION
Both ceftazidime and imipenem have been shown to be safe and effective as initial monotherapy for febrile neutropenic patients (1, 2, 10, 14) . However, there are considerable differences in their spectra of antibacterial activity. Imipenem appears to be more effective than ceftazidime against gram-positive organisms (7) . Both drugs are, in general, very active against gram-negative organisms, including Pseudomonas spp., although ceftazidime is probably the more active drug against Pseudomonas spp. (3, 12, 14) . Patients in this study who did not respond to monotherapy were given additional cloxacillin and amikacin empirically. Cloxacillin was used to cover some of the resistant gram-positive organisms such as Staphylococcus aureus. Other antimicrostudy (14) . Although a maximum dose of 4 g daily was used bial agents such as vancomycin and teicoplanin are more for imipenem in some other trials, this higher dose appeared active against infections caused by gram-positive organisms.
to be associated with an increased risk of central nervous The early empirical use of these expensive agents may be system toxicity. Since a dose of 2 g of imipenem daily has justified, as there appeared to be a pattern of increasing been shown in our previous pilot study (10) to be safe and incidence of infections caused by gram-positive organisms, effective, this lower dose was used in the present study. in neutropenic patients (8, 15) . In this study, the use of
The overall response of fever to imipenem was signifivancomycin was reserved for those with documented infeccantly better (P = 0.04) than the response to ceftazidime. tions caused by methicillin-resistant staphylococci. Amika-
The response rate of 77% to imipenem is comparable to the cin was used for treatment against some of the resistant rate of 70% we found in our previous pilot study (10) . Also, gram-negative organisms, especially Pseudomonas spp. (5) .
the response rate of 56% to ceftazidime was comparable to Because of the possible synergistic effect, ceftazidime or that given in another report (14) . The difference in responses imipenem was continued after cloxacillin and amikacin were was more obvious in patients with microbiologically docuadded (5, 13, 16) .
mented infections. Because of the small number of patients As neutropenic infection is a serious condition, a relain each subgroup, it was difficult to interpret the differences tively high dose of antibiotic is usually used (13, 16) . The in responses among the different clinical sites of infection maximum dose of 6 g of ceftazidime daily was used in this and different infective organisms. However, while the (6, 8, 20) . It appears that vancomycin or teicloplanin should be included for infections possibly caused by gram-positive organisms in the initial management of febrile episodes in neutropenic patients, especially if they have an indwelling intravenous catheter (8, 20) . Pseudomonal infections remain troublesome and accounted more often for the relapses and superinfections following imipenem therapy (Table 5 ). This may be the subgroup of patients in whom early use of a combination of two antipseudomonal antibiotics may improve treatment success and prevent relapses (5, 12 
